Literature DB >> 22740085

Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial-mesenchymal transition in squamous cell carcinoma.

Songmei Geng1, Yuanyuan Guo2, Qianqian Wang2, Lan Li2, Jianli Wang3.   

Abstract

Increasing evidences have indicated that only a phenotypic subset of cancer cells, termed as the cancer stem cells (CSCs), is capable of initiating tumor growth and provide a reservoir of cells that cause tumor recurrence after therapy. Epithelial-mesenchymal transition (EMT), a cell type change from an epithelial cobblestone phenotype to an elongated fibroblastic phenotype, plays a critical role not only in tumor metastasis but also in tumor recurrence and contributes to drug resistance. Accumulating evidence has shown that cells with an EMT phenotype are rich sources for CSCs, suggesting a biological link between EMT and CSCs; thus study on the link will help understand the cellular and molecular mechanisms of tumor metastasis and drug resistance. CD29 is involved in EMT through cross-talk with cadherins and CD44 has been reported as a successful used marker for CSCs. Here, we try to address whether combination of CD29 and CD44 could be used to identify cancer stem-like cells undergoing EMT in squamous cell carcinoma (SCC) and compare the molecular differences between CD29high/CD44high and CD29low/CD44low cells in SCC. Expression pattern of CD29 and CD44 was analyzed in tissues of skin SCC and cultured A431 cells by immunostaining. Subtype cells of CD29high/CD44high and CD29low/CD44low A431 were sorted by fluorescence-activated cell sorting and proliferating abilities were assayed by cell counting, colony forming and tumorigenicity in NOD/SCID mice. Finally, to probe more deeply into the molecular differences between CD29high/CD44high and CD29low/CD44low A431 cells, gene microarray analysis was applied to compare gene expression profiling. Staining of CD29 and CD44 showed similar heterogeneous expression pattern with positive cells located in the invasion front of SCC tissue as well as in cultured A431 cells. Sorted CD29high/CD44high A431 cells had higher proliferating ability in vitro and in NOD/SCID mice as compared with CD29low/CD44low cells. Gene profiling identified differentiated gene expressions between CD29high/CD44high and CD29low/CD44low A431 cells. These genes are involved in cell cycle, cell malignant transformation, metastasis, drug resistance and EMT, implying that CD29high/CD44high cells have properties of CSCs and EMT. Our present results demonstrated heterogeneous gene expression patterns and different biological behavior in SCC. Combination of CD29 and CD44 can be used as markers to enrich CSCs in human SCC. Moreover, CD29high/CD44high cells exhibit molecular characteristics of EMT, suggesting that CSC-associated pathways were involved in EMT. Studies on correlation of CSCs and the cells undergoing EMT may explain some aspects of tumor progression and drug resistance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22740085     DOI: 10.1007/s00403-012-1260-2

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  31 in total

1.  Elevation of MiR-9-3p suppresses the epithelial-mesenchymal transition of nasopharyngeal carcinoma cells via down-regulating FN1, ITGB1 and ITGAV.

Authors:  Yu Ding; Yinghua Pan; Shan Liu; Feng Jiang; Junbo Jiao
Journal:  Cancer Biol Ther       Date:  2017-06-14       Impact factor: 4.742

2.  The Mesenchymal State Predicts Poor Disease-Free Survival in Resectable Non-Small Cell Lung Cancer.

Authors:  Kunal Mehta; Erika Moravcikova; David McFall; James D Luketich; Arjun Pennathur; Albert D Donnenberg; Vera S Donnenberg
Journal:  Ann Thorac Surg       Date:  2017-05-09       Impact factor: 4.330

3.  Biological characterization of the UW402, UW473, ONS-76 and DAOY pediatric medulloblastoma cell lines.

Authors:  Ricardo Bonfim-Silva; Karina Bezerra Salomão; Thais Valéria Costa de Andrade Pimentel; Camila Cristina Branquinho de Oliveira Menezes; Patrícia Vianna Bonini Palma; Aparecida Maria Fontes
Journal:  Cytotechnology       Date:  2019-07-26       Impact factor: 2.058

4.  Concerted loss of TGFβ-mediated proliferation control and E-cadherin disrupts epithelial homeostasis and causes oral squamous cell carcinoma.

Authors:  Thomas Andl; Grégoire F Le Bras; Nicole F Richards; Gillian L Allison; Holli A Loomans; M Kay Washington; Frank Revetta; Rebecca K Lee; Chase Taylor; Harold L Moses; Claudia D Andl
Journal:  Carcinogenesis       Date:  2014-09-18       Impact factor: 4.944

5.  β1 integrin mediates colorectal cancer cell proliferation and migration through regulation of the Hedgehog pathway.

Authors:  Jia Song; Jixiang Zhang; Jing Wang; Jun Wang; Xufeng Guo; Weiguo Dong
Journal:  Tumour Biol       Date:  2014-11-12

6.  The role of CD29-ILK-Akt signaling-mediated epithelial-mesenchymal transition of liver epithelial cells and chemoresistance and radioresistance in hepatocellular carcinoma cells.

Authors:  Xiaorong Jiang; Jingxia Wang; Kaili Zhang; Siyuan Tang; Caiping Ren; Yuxiang Chen
Journal:  Med Oncol       Date:  2015-03-25       Impact factor: 3.064

7.  High-level β1-integrin expression in a subpopulation of highly tumorigenic oral cancer cells.

Authors:  Hsiang-Chun Lin; Chao-Liang Wu; Yuh-Ling Chen; Jehn-Shyun Huang; Tung-Yiu Wong; Kuo Yuan
Journal:  Clin Oral Investig       Date:  2013-08-25       Impact factor: 3.573

Review 8.  Cancer stem cells in human digestive tract malignancies.

Authors:  Fatemeh B Rassouli; Maryam M Matin; Morvarid Saeinasab
Journal:  Tumour Biol       Date:  2015-10-07

9.  Premature aging induced by radiation exhibits pro-atherosclerotic effects mediated by epigenetic activation of CD44 expression.

Authors:  Donna Lowe; Kenneth Raj
Journal:  Aging Cell       Date:  2014-07-25       Impact factor: 9.304

Review 10.  Characterization of Nestin, a Selective Marker for Bone Marrow Derived Mesenchymal Stem Cells.

Authors:  Liang Xie; Xin Zeng; Jing Hu; Qianming Chen
Journal:  Stem Cells Int       Date:  2015-07-06       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.